北京大学学报(医学版) ›› 2020, Vol. 52 ›› Issue (6): 1048-1055. doi: 10.19723/j.issn.1671-167X.2020.06.010

• 论著 • 上一篇    下一篇

银屑病关节炎抑郁和焦虑患病情况及相关因素

耿研,宋志博,张晓慧,邓雪蓉,王昱,张卓莉()   

  1. 北京大学第一医院风湿免疫科,北京 100034
  • 收稿日期:2020-08-03 出版日期:2020-12-18 发布日期:2020-12-13
  • 通讯作者: 张卓莉 E-mail:zhuoli.zhang@126.com
  • 基金资助:
    国家自然科学基金(81901646);国家自然科学基金(81771740);国家自然科学基金(81971524);北京大学第一医院青年临床研究专项基金(2019CR28)

Depression and anxiety in patients with psoriatic arthritis: Prevalence and associated factors

Yan GENG,Zhi-bo SONG,Xiao-hui ZHANG,Xue-rong DENG,Yu WANG,Zhuo-li ZHANG()   

  1. Department of Rheumatology and Clinical Immunology, Peking University First Hospital, Beijing 100034, China
  • Received:2020-08-03 Online:2020-12-18 Published:2020-12-13
  • Contact: Zhuo-li ZHANG E-mail:zhuoli.zhang@126.com
  • Supported by:
    National Natural Science Foundation of China(81901646);National Natural Science Foundation of China(81771740);National Natural Science Foundation of China(81971524);Youth Clinical Research Project of Peking University First Hospital(2019CR28)

摘要:

目的:评估银屑病关节炎(psoriatic arthritis,PsA)患者抑郁及焦虑的患病率,比较与类风湿关节炎(rheumatoid arthritis,RA)患者之间的差异,探索PsA患者发生抑郁及焦虑的相关因素。方法:连续入选2018年5月至2019年9月就诊于北京大学第一医院风湿免疫科门诊的PsA和RA患者,采用抑郁自评量表和焦虑自评量表评估患者抑郁和焦虑情况,并进行对比。收集PsA患者的人口学及临床数据,包括性别、年龄、病程、疾病活动度及用药情况等,同时应用能量多普勒与灰阶超声评价关节及附着点病变。采用多因素Logistic回归分析相关因素。结果:入选114例PsA患者,37例(32.5%)患有精神障碍,其中36例(31.6%)合并抑郁,15例(13.2%)合并焦虑。与201名RA患者相比较,PsA患者合并抑郁的比例更高(31.6% vs. 18.9%,P=0.011), 经过校正分析发现PsA比RA发生抑郁的风险更高(校正OR=2.7,95%CI:1.1~6.4);合并焦虑患者的比例也较RA有升高趋势(13.2% vs. 8.5%,P=0.185),但差异无统计学意义。在PsA患者中,年龄(OR=0.95,P=0.008)、银屑病病程(OR=0.94,P=0.018)、疼痛视觉模拟评分(OR=1.47,P=0.011)、银屑病皮损面积及严重程度指数(psoriasis area and severity index,PASI)(OR=1.07,P=0.007)、超声附着点炎阳性(OR=4.13,P=0.009)是抑郁的相关因素;PASI(OR=1.07,P=0.001)是焦虑的相关因素。结论:PsA患者患抑郁与焦虑的比例较高,其中抑郁患病风险更是高于RA患者。年龄小、银屑病病程短、银屑病皮疹重、疼痛评分高、存在超声附着点炎症的PsA患者更容易出现抑郁,银屑病皮疹重是PsA患者发生焦虑的相关因素。

关键词: 银屑病关节炎, 抑郁, 焦虑, 患病率

Abstract:

Objective: To determine the prevalence of depression and anxiety in patients with psoriatic arthritis (PsA), to investigate whether there is a difference in the prevalence of depression and anxiety between PsA and rheumatoid arthritis (RA) patients and to identify associated risk factors for depression and anxiety in PsA patients. Methods: PsA and RA patients who visited Department of Rheumatology and Clinical Immunology in Peking University First Hospital from May 2018 to Sep 2019 were recruited. Self-rating anxiety scale and self-rating depression scale were surveyed and compared between PsA and RA patients. Demographics and clinical features including age, gender, disease duration, disease activity score, psoriasis area and severity index (PASI), and medical application were collected. Power Doppler and grey-scale ultrasound of joints, tenosynovitis and enthesis were performed. Multivariate Logistic regression was used to identify the factors associated with mood disorders and the odds ratio of depression and anxiety between the PsA and RA patients. Results: Among the 114 enrolled PsA patients, 37 (32.5%) had mood disorders, in which 36 (31.6%) with depression and 15 (13.2%) with anxiety. Compared with 201 RA patients, PsA patients showed greater odds for depression [adjusted OR (95%CI): 2.7 (1.1-6.4)]. Depression was more often observed in the PsA than in the RA patients (31.6% vs. 18.9%, P=0.011). The similar trend for anxiety was also observed, although the difference was insignificant (13.2% vs. 8.5%, P=0.185). Age (OR=0.95, P=0.008), psoriasis duration (OR=0.94, P=0.018), pain visual analogue scale (OR=1.47, P=0.011), PASI score (OR=1.07, P=0.007) and presence of ultrasound enthesitis (OR=4.13, P=0.009) were identified as factors associated with depression in the PsA patients. PASI score (OR=1.07, P=0.001) was identified as associated factor for anxiety in the PsA patients. Conclusion: The prevalence of depression and anxiety is elevated in PsA patients. Depression is significantly more prevalent in PsA patients than in RA patients. Younger age, shorter psoriasis duration, worse pain and presence of ultrasound enthesitis are associated with depression, while severe psoriasis rash is associated with both depression and anxiety in PsA patients.

Key words: Psoriatic arthritis, Depression, Anxiety, Prevalence

中图分类号: 

  • R593.2

表1

PsA、RA患者临床特点及抑郁和焦虑患病情况比较"

Items PsA (n=114) RA (n=201) P
Female 55 (48.2) 166 (82.6) <0.001
Age/years 47.6±13.5 49.5±13.0 0.222
Disease duration/years 14.0 (7.0, 24.3) 3.4 (1.0, 10.0) <0.001
TJC 28 3.0 (1.0, 8.0) 2.0 (0.0, 6.5) 0.253
SJC 28 2.0 (0.0, 6.0) 1.0 (0.0, 3.5) 0.054
ESR/(mm/h) 11.5 (5.0, 27.3) 21.0 (10.0, 40.0) <0.001
CRP/(mg/L) 5.5 (2.0, 15,6) 6.1 (2.6, 14.8) 0.176
PGA (0-10) 4.0 (2.0, 6.0) 3.0 (2.0, 6.0) 0.276
EGA (0-10) 3.0 (2.0, 5.0) 2.0 (1.0, 5.0) 0.124
Pain VAS (0-10) 3.8 (2.0, 5.0) 3.0 (1.3, 5.0) 0.615
DAS28-CRP 3.4±1.5 3.6±1.6 0.419
SDAI 14.1 (7.3, 24.4) 10.6 (5.6, 24.0) 0.067
HAQ 1.0 (0.0, 8.0) 4.0 (0.5, 15.0) 0.001
PASI 3.2 (0.8, 9.4) 0.0 (0.0, 0.0) <0.001
Mood disorder
Depression 36 (31.6) 38 (18.9) <0.001
Anxiety 15 (13.2) 17 (8.5) 0.185
Cigarette smoking <0.001
Non-smokers 76 (66.7) 170 (84.6)
Ex-smokers 14 (12.3) 15 (7.5)
Current smokers 24 (21.1) 16 (8.0)
csDMARDs used <0.001
csDMARDs-naive 14 (12.3) 66 (32.8)
Single csDMARDs 80 (70.2) 49 (24.4)
Combined csDMARDs 20 (17.5) 86 (42.8)
Biological DMARDs used 2 (1.8) 4 (2.0) 0.882
Metabolic syndrome 38 (33.3) 19 (9.5) <0.001

表2

预测抑郁患病风险模型(PsA与RA风险比,Logistic回归)"

Items OR 95%CI P
PsA vs. RA 2.70 1.14-6.44 0.025
Age 0.97 0.95-0.99 0.004
Disease duration 0.94 0.91-0.98 0.002
SDAI 1.00 0.98-1.03 0.977
HAQ 1.04 1.01-1.08 0.031
PASI 1.06 1.02-1.11 0.009

表3

抑郁与非抑郁PsA患者临床表现和超声特点比较"

Items PsA with depression (n=36) PsA without depression (n=78) P
Female 18 (50.0) 37 (47.40) 0.799
Age/years 41.6±14.5 50.4±12.1 0.001
Disease duration of PsO/years 10.0 (5.3, 15.8) 15.5 (7.8, 29.3) 0.048
Disease duration of PsA/years 3.5 (1.0, 9.5) 3.3 (1.2, 8.5) 0.932
TJC 68 3.0 (1.3, 9.8) 2.5 (1.0, 8.0) 0.495
SJC 66 3.0 (0.3, 6.0) 2.0 (0.0, 5.3) 0.641
Pain VAS (0-10) 4.0 (3.0, 6.0) 3.0 (2.0, 5.0) 0.015
PGA (0-10) 5.0 (3.0, 6.8) 4.0 (2.0, 5.0) 0.059
EGA (0-10) 3.0 (2.0, 5.0) 3.0 (1.5, 4.3) 0.207
CRP/(mg/L) 5.7 (2.4, 20.3) 4.6 (1.9, 15.6) 0.592
ESR/(mm/h) 12.5 (7.0, 27.0) 11.0 (5.0, 28.3) 0.676
DAPSA 17.4 (8.7, 27.7) 14.2 (7.8, 24.4) 0.239
HAQ 2.5 (0.0, 8.8) 1.0 (0.0, 7.3) 0.305
PSAI 4.4 (1.2, 29.4) 2.6 (0.7, 7.7) 0.018
Ultrasonographic feathers
Synovitis GS total score 1.5 (0.0, 3.8) 1.5 (0.0, 4.0) 0.957
Synovitis PD total score 0.0 (0.0, 1.0) 0.0 (0.0, 2.0) 0.414
Tenosynovitis GS total score 0.0 (0.0, 2.0) 0.0 (0.0, 2.0) 0.279
Tenosynovitis PD total score 0.0 (0.0, 1.0) 0.0 (0.0, 1.0) 0.528
Presence of enthesitis 23 (63.9) 33 (42.3) 0.032
Bone erosion 16 (44.4) 32 (41.0) 0.731
csDMARDs used 0.165
csDMARDs-naive 4 (11.1) 10 (11.8)
Single csDMARD 22 (61.1) 58 (74.4)
Combined csDMARDs 10 (27.8) 10 (12.8)
Biological DMARDs used 1 (2.8) 1 (1.3) 0.534
NSAIDs used 12 (33.3) 19 (24.4) 0.317
BMI/(kg/m2) 23.2±2.8 24.0±3.0 0.178
Waist circumference/cm 82.3±10.5 84.6±8.5 0.250
Onychosis 16 (44.6) 53 (62.4) 0.069
Ophthalmitis 2 (5.6) 1 (1.3) 0.234
Metabolic syndrome 8 (22.2) 30 (38.5) 0.087
Cigarette smoking 0.902
Non-smoker 23 (63.9) 53 (67.9)
Ex-smoker 5 (13.9) 9 (11.5)
Current smoker 8 (22.2) 16 (20.5)
Family history of PsO/PsA 17 (47.2) 23 (29.5) 0.065

表4

焦虑与非焦虑PsA患者临床表现和超声特点比较"

Items PsA with anxiety (n=15) PsA without anxiety (n=99) P
Female 8 (53.3) 47 (47.5) 0.672
Age/years 42.8±16.8 48.3±12.8 0.140
Disease duration of PsO/years 11.0 (4.0, 20.0) 14.0 (8.0, 26.0) 0.401
Disease duration of PsA/years 7.0 (1.0, 12.0) 3.0 (1.0, 8.0) 0.233
TJC 68 2.0 (0.0, 10.0) 3.0 (1.0, 8.0) 0.939
SJC 66 2.0 (0.0, 6.0) 2.0 (0.0, 5.0) 0.963
Pain VAS (0-10) 3.0 (3.0, 6.0) 4.0 (2.0, 5.0) 0.343
PGA (0-10) 3.0 (2.0, 6.0) 4.0 (2.0, 6.0) 0.922
EGA (0-10) 2.0 (2.0, 5.0) 3.0 (2.0, 5.0) 0.806
CRP/(mg/L) 5.5 (1.3, 11.9) 5.4 (2.0, 15.8) 0.672
ESR/(mm/h) 11.0 (5.0, 21.0) 12.0 (5.0, 29.0) 0.540
DAPSA 14.5 (5.1, 31.5) 15.7 (8.3, 24.4) 0.983
HAQ 3.0 (0.0, 14.0) 1.0 (0.0, 7.0) 0.263
PSAI 7.6 (0.6, 39.0) 3.0 (0.8, 8.4) 0.047
Ultrasonographic feathers
Synovitis GS total score 0.0 (0.0, 2.0) 2.0 (0.0, 4.0) 0.147
Synovitis PD total score 0.0 (0.0, 0.0) 0.0 (0.0, 2.0) 0.270
Tenosynovitis GS total score 0.0 (0.0, 2.0) 0.0 (0.0, 2.0) 0.608
Tenosynovitis PD total score 0.0 (0.0, 0.0) 0.0 (0.0, 1.0) 0.200
Presence of enthesitis 7 (46.7) 49 (49.5) 0.838
Bone erosion 5 (33.3) 43 (43.4) 0.460
csDMARDs used 0.068
csDMARDs-naive 2 (13.3) 12 (12.1)
Single csDMARDs 7 (46.7) 73 (73.7)
Combined csDMARDs 6 (40.0) 14 (14.1)
Biological DMARDs used 1 (6.7) 1 (1.0) 0.617
NSAIDs used 3 (20.0) 28 (28.3) 0.718
BMI/(kg/m2) 24.3±2.4 23.6±3.0 0.417
Waist circumference/cm 84.7±11.8 83.7±8.8 0.734
Onychosis 6 (40.0) 58 (58.6) 0.176
Ophthalmitis 0 3 (3.0) 0.652
Metabolic syndrome 6 (40.0) 32 (32.3) 0.557
Cigarette smoking 0.266
Non-smokers 11 (73.3) 65 (65.7)
Ex-smokers 3 (20.0) 11 (11.1)
Current smokers 1 (6.7) 23 (23.2)
Family history of PsO/PsA 7 (46.7) 33 (33.3) 0.313

表5

PsA患者发生抑郁/焦虑的相关因素(多因素Logistic回归)"

Items OR 95%CI P
Associated factors for depression
Age 0.95 0.91-0.99 0.008
Disease duration 0.94 0.90-0.99 0.018
Pain VAS 1.47 1.09-1.98 0.011
PASI 1.07 1.02-1.13 0.007
Presence of ultrasound enthesitis 4.13 1.42-12.05 0.009
Associated factor for anxiety
PASI 1.07 1.03-1.12 0.001
[1] Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: Epidemiology, clinical features, course, and outcome[J]. Ann Rheum Dis, 2005,64(Suppl 2):14-17.
[2] Giacomelli R, Gorla R, Trotta F, et al. Quality of life and unmet needs in patients with inflammatory arthropathies: Results from the multicentre, observational RAPSODIA study[J]. Rheumatology (Oxford), 2015,54(5):792-797.
doi: 10.1093/rheumatology/keu398
[3] Wu JJ, Penfold RB, Primatesta P, et al. The risk of depression, suicidal ideation and suicide attempt in patients with psoriasis, psoriatic arthritis or ankylosing spondylitis[J]. J Eur Acad Dermatol Venereol, 2017,31(7):1168-1175.
doi: 10.1111/jdv.14175 pmid: 28214371
[4] Kamalaraj N, El-Haddad C, Hay P, et al. Systematic review of depression and anxiety in psoriatic arthritis[J]. Int J Rheum Dis, 2019,22(6):967-973.
doi: 10.1111/1756-185X.13553 pmid: 31025820
[5] Freire M, Rodriguez J, Moller I, et al. Prevalence of symptoms of anxiety and depression in patients with psoriatic arthritis attending rheumatology clinics[J]. Reumatol Clin, 2011,7(1):20-26.
doi: 10.1016/j.reuma.2010.03.003
[6] Husted JA, Gladman DD, Farewell VT, et al. Health-related quality of life of patients with psoriatic arthritis: A comparison with patients with rheumatoid arthritis[J]. Arthritis Rheum, 2001,45(2):151-158.
doi: 10.1002/1529-0131(200104)45:2<151::AID-ANR168>3.0.CO;2-T pmid: 11324779
[7] Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: Development of new criteria from a large international study[J]. Arthritis Rheum, 2006,54(8):2665-2673.
pmid: 16871531
[8] Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis[J]. Arthritis Rheum, 1988,31(3):315-324.
pmid: 3358796
[9] Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: An American College of Rheumatology / European League Against Rheumatism collaborative initiative[J]. Ann Rheum Dis, 2010,69(9):1580-1588.
doi: 10.1136/ard.2010.138461 pmid: 20699241
[10] Zung WW. The depression status inventory: An adjunct to the self-rating depression scale[J]. J Clin Psychol, 1972,28(4):539-543.
doi: 10.1002/1097-4679(197210)28:4<539::aid-jclp2270280427>3.0.co;2-s pmid: 5080837
[11] Bruce B, Fries JF. The Health Assessment Questionnaire (HAQ)[J]. Clin Exp Rheum, 2005,23(5 Suppl 39):14-18.
[12] Schmitt J, Wozel G. The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis[J]. Dermatology, 2005,210(3):194-199.
doi: 10.1159/000083509 pmid: 15785046
[13] Makinen H, Kautiainen H, Hannonen P, et al. Disease activity score 28 as an instrument to measure disease activity in patients with early rheumatoid arthritis[J]. J Rheum, 2007,34(10):1987-1991.
pmid: 17611990
[14] Smolen JS, Breedveld FC, Schiff MH, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice[J]. Rheumatology (Oxford), 2003,42(2):244-257.
doi: 10.1093/rheumatology/keg072
[15] Smolen JS, Schoels M, Aletaha D. Disease activity and response assessment in psoriatic arthritis using the disease activity index for psoriatic arthritis (DAPSA). A brief review[J]. Clin Exp Rheum, 2015,33(5 Suppl 93):48-50.
[16] Lu B, Rho YH, Cui J, et al. Associations of smoking and alcohol consumption with disease activity and functional status in rheumatoid arthritis[J]. J Rheum, 2014,41(1):24-30.
doi: 10.3899/jrheum.130074 pmid: 24293566
[17] Alberti KG, Zimmet P, Shaw J. Metabolic syndrome: A new world-wide definition. A consensus statement from the International Diabetes Federation[J]. Diabet Med, 2006,23(5):469-480.
pmid: 16681555
[18] Wakefield RJ, Balint PV, Szkudlarek M, et al. Musculoskeletal ultrasound including definitions for ultrasonographic pathology[J]. J Rheum, 2005,32(12):2485-2487.
pmid: 16331793
[19] Szkudlarek M, Court-Payen M, Strandberg C, et al. Power Doppler ultrasonography for assessment of synovitis in the metacarpophalangeal joints of patients with rheumatoid arthritis: A comparison with dynamic magnetic resonance imaging[J]. Arthritis Rheum, 2001,44(9):2018-2023.
doi: 10.1002/1529-0131(200109)44:9<2018::AID-ART350>3.0.CO;2-C pmid: 11592362
[20] Naredo E, D'Agostino MA, Wakefield RJ, et al. Reliability of a consensus-based ultrasound score for tenosynovitis in rheumatoid arthritis[J]. Ann Rheum Dis, 2013,72(8):1328-1334.
doi: 10.1136/annrheumdis-2012-202092
[21] Michelsen B, Kristianslund EK, Sexton J, et al. Do depression and anxiety reduce the likelihood of remission in rheumatoid arthritis and psoriatic arthritis? Data from the prospective multicentre NOR-DMARD study[J]. Ann Rheum Dis, 2017,76(11):1906-1910.
doi: 10.1136/annrheumdis-2017-211284 pmid: 28733473
[22] Lowe B, Willand L, Eich W, et al. Psychiatric comorbidity and work disability in patients with inflammatory rheumatic diseases[J]. Psychosom Med, 2004,66(3):395-402.
pmid: 15184703
[23] Baxter AJ, Scott KM, Vos T, et al. Global prevalence of anxiety disorders: A systematic review and meta-regression[J]. Psychol Med, 2013,43(5):897-910.
doi: 10.1017/S003329171200147X
[24] Zhao SS, Miller N, Harrison N, et al. Systematic review of mental health comorbidities in psoriatic arthritis[J]. Clin Rheumatol, 2020,39(1):217-225.
doi: 10.1007/s10067-019-04734-8 pmid: 31486931
[25] Zusman EZ, Howren AM, Park JYE, et al. Epidemiology of depression and anxiety in patients with psoriatic arthritis: A systema-tic review and meta-analysis [J/OL]. Semin Arthritis Rheum, (2020-02-13) [2020-05-15]. doi: 10.1016/j.semarthrit.2020.02.001.
[26] Bacconnier L, Rincheval N, Flipo RM, et al. Psychological distress over time in early rheumatoid arthritis: Results from a longitudinal study in an early arthritis cohort[J]. Rheumatology (Oxford), 2015,54(3):520-527.
doi: 10.1093/rheumatology/keu371
[27] Overman CL, Bossema ER, van Middendorp H, et al. The prospective association between psychological distress and disease activity in rheumatoid arthritis: A multilevel regression analysis[J]. Ann Rheum Dis, 2012,71(2):192-197.
doi: 10.1136/annrheumdis-2011-200338
[28] Rosenblat JD, Cha DS, Mansur RB, et al. Inflamed moods: A review of the interactions between inflammation and mood disorders[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2014(53):23-34.
[29] Dowlatshahi EA, Wakkee M, Arends LR, et al. The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: A systematic review and meta-analysis[J]. J Invest Dermatol, 2014,134(6):1542-1551.
pmid: 24284419
[30] McDonough E, Ayearst R, Eder L, et al. Depression and anxiety in psoriatic disease: Prevalence and associated factors[J]. J Rheum, 2014,41(5):887-896.
doi: 10.3899/jrheum.130797 pmid: 24692521
[31] Riente L, Carli L, Delle Sedie A. Ultrasound imaging in psoriatic arthritis and ankylosing spondylitis[J]. Clin Exp Rheum, 2014,32(1 Suppl 80):26-33.
[32] Freeston JE, Coates LC, Helliwell PS, et al. Is there subclinical enthesitis in early psoriatic arthritis? A clinical comparison with power doppler ultrasound[J]. Arthritis Care Res (Hoboken), 2012,64(10):1617-1621.
doi: 10.1002/acr.21733
[33] Miller AH, Haroon E, Raison CL, et al. Cytokine targets in the brain: Impact on neurotransmitters and neurocircuits[J]. Depress Anxiety, 2013,30(4):297-306.
pmid: 23468190
[34] Dregan A, Matcham F, Harber-Aschan L, et al. Common mental disorders within chronic inflammatory disorders: A primary care database prospective investigation[J]. Ann Rheum Dis, 2019,78(5):688-695.
pmid: 30846444
[35] Sinnathurai P, Buchbinder R, Hill C, et al. Comorbidity in pso-riatic arthritis and rheumatoid arthritis[J]. Intern Med J, 2018,48(11):1360-1368.
doi: 10.1111/imj.14046 pmid: 30047189
[1] 宋志博,耿研,邓雪蓉,张晓慧,张卓莉. 肌肉骨骼超声在指导银屑病关节炎临床分型中的价值[J]. 北京大学学报(医学版), 2021, 53(6): 1061-1066.
[2] 吴俊慧,陈泓伯,武轶群,吴瑶,王紫荆,吴涛,王梦莹,王斯悦,王小文,王伽婷,于欢,胡永华. 2015—2017年北京市2型糖尿病患者骨关节炎患病的相关因素[J]. 北京大学学报(医学版), 2021, 53(3): 518-522.
[3] 樊理诗,高敏,Edwin B.FISHER,孙昕霙. 北京市通州区和顺义区747例2型糖尿病患者生存质量影响因素[J]. 北京大学学报(医学版), 2021, 53(3): 523-529.
[4] 王一帆,范稹,成姚斌,金月波,霍阳,何菁. 原发性干燥综合征患者睡眠障碍的相关影响因素[J]. 北京大学学报(医学版), 2020, 52(6): 1063-1068.
[5] 许璐,陈璐,樊东升,冯菁楠,刘立立,詹思延,王胜锋. 基于15省城镇医疗保险数据测算我国成人进行性肌萎缩患病率[J]. 北京大学学报(医学版), 2020, 52(3): 521-526.
[6] 邓思危,陈则亦,刘志科,王健,卓琳,高双庆,余家阔,詹思延. 基于城镇医保数据库骨关节伤病的流行病学研究[J]. 北京大学学报(医学版), 2020, 52(3): 527-534.
[7] 易端,朱薇,孟秀丽,刘晓光,李水清,祝斌,贾东林. 慢性腰腿痛患者微创术前焦虑,抑郁状态及相关影响因素分析[J]. 北京大学学报(医学版), 2020, 52(2): 285-289.
[8] 代丽怡,巩丹丹,赵金霞. 类风湿因子或抗环瓜氨酸化多肽抗体阳性银屑病关节炎患者的临床特点[J]. 北京大学学报(医学版), 2019, 51(6): 1008-1013.
[9] 李玉慧,苏波,林福安,费雅楠,于笑霞,范文强,陈海英,张学武,贾园. 银屑病关节炎患者就医行为及治疗现状的多中心调查[J]. 北京大学学报(医学版), 2019, 51(6): 1014-1018.
[10] 刘颖,曾祥柱,王筝,张函,王希林,袁慧书. 三维动脉自旋标记技术评价抑郁合并高血压患者脑血流灌注[J]. 北京大学学报(医学版), 2019, 51(2): 260-264.
[11] 王天骄,刘宇,关明. 咪达唑仑联合丙泊酚靶控输注静脉镇静对拔除下颌第三磨牙患者焦虑水平的影响[J]. 北京大学学报(医学版), 2017, 49(6): 1044-1049.
[12] 石慧峰, 张敬旭, 张嵘, 王晓莉. 中国0~6岁儿童孤独症谱系障碍患病率的meta分析[J]. 北京大学学报(医学版), 2017, 49(5): 798-806.
[13] 雷杰,刘木清,傅开元. 睡眠问题、焦虑及压力是颞下颌关节紊乱病肌筋膜疼痛发病的风险指标[J]. 北京大学学报(医学版), 2016, 48(4): 692-696.
[14] 余灿清,陈怡平,吕筠,郭彧,Paul Sherliker,卞铮,周汇燕,谭云龙,陈君石,陈铮鸣,李立明. 中国30~79岁成人抑郁障碍与冠心病和脑卒中的关联[J]. 北京大学学报(医学版), 2016, 48(3): 465-471.
[15] 郁静茹, 金蕾, 肖利华, 靳蕾. 北京通州区神经管缺陷患病率及其与监测时限的关系[J]. 北京大学学报(医学版), 2015, 47(6): 1042-1045.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] 田增民, 陈涛, Nanbert ZHONG, 李志超, 尹丰, 刘爽. 神经干细胞移植治疗遗传性小脑萎缩的临床研究(英文稿)[J]. 北京大学学报(医学版), 2009, 41(4): 456 -458 .
[2] 郭岩, 谢铮. 用一代人时间弥合差距——健康社会决定因素理论及其国际经验[J]. 北京大学学报(医学版), 2009, 41(2): 125 -128 .
[3] 成刚, 钱振华, 胡军. 艾滋病项目自愿咨询检测的技术效率分析[J]. 北京大学学报(医学版), 2009, 41(2): 135 -140 .
[4] 卢恬, 朱晓辉, 柳世庆, 郑杰, 邱晓彦. 白细胞介素2促进宫颈癌细胞系HeLaS3免疫球蛋白G的表达[J]. 北京大学学报(医学版), 2009, 41(2): 158 -161 .
[5] 袁惠燕, 张苑, 范田园. 离子交换型栓塞微球及其载平阳霉素的制备与性质研究[J]. 北京大学学报(医学版), 2009, 41(2): 217 -220 .
[6] 徐莉, 孟焕新, 张立, 陈智滨, 冯向辉, 释栋. 侵袭性牙周炎患者血清中抗牙龈卟啉单胞菌的IgG抗体水平的研究[J]. 北京大学学报(医学版), 2009, 41(1): 52 -55 .
[7] 董稳, 刘瑞昌, 刘克英, 关明, 杨旭东. 氯诺昔康和舒芬太尼用于颌面外科术后自控静脉镇痛的比较[J]. 北京大学学报(医学版), 2009, 41(1): 109 -111 .
[8] 祁琨, 邓芙蓉, 郭新彪. 纳米二氧化钛颗粒对人肺成纤维细胞缝隙连接通讯的影响[J]. 北京大学学报(医学版), 2009, 41(3): 297 -301 .
[9] Jian-wei GU, Emily YOUNG, Zhi-jun PAN, Kevan B. TUCKER, Megan SHPARAGO, Min HUANG, Amelia Purser BAILEY. SD大鼠长期高盐饮食可导致其高血压并改变肾细胞因子基因表达谱[J]. 北京大学学报(医学版), 2009, 41(5): 505 -515 .
[10] 李宏亮*, 安卫红*, 赵扬玉, 朱曦. 妊娠合并高脂血症性胰腺炎行血液净化治疗1例[J]. 北京大学学报(医学版), 2009, 41(5): 599 -601 .